Targeting the inflammasome and adenosine type-3 receptors improves outcome of antibiotic therapy in murine anthrax

Figure 2 Survival of B. anthracis Sterne-challenged DBA/2 mice after treatment. Mice challenged with B. anthracis Sterne spores (i.p.) were treated (s.c.) with indicated daily bolus doses. A: A3R agonist Cl-IB-MECA (0.05, 0.15 and 0.3 mg/kg); B: combination of Cl-IB-MECA (0.05, 0.15 and 0.3 mg/kg) with ciprofloxacin (50 mg/kg); C, D: Caspase-1 inhibitor YVAD (C: 2.5 mg/kg; D: 12.5 mg/kg) in combination with ciprofloxacin (50 mg/kg); E: Triple combination of caspase-1 inhibitor YVAD (2.5 mg/kg), A3AR agonist Cl-IB-MECA (0.15 mg/kg) and ciprofloxacin (50 mg/kg); F: Triple combination of caspase-1 inhibitor YVAD (12.5 mg/kg), A3AR agonist Cl-IB-MECA (0.3 mg/kg) and ciprofloxacin (50 mg/kg). Kaplan–Meier statistical log-rank analysis was used for survival data.